Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Gimeno, Eva
NCT05049473: Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.	Recruiting	2	100	Europe	Rituximab, Methotrexate, Dexamethasone, Iphosphamid, Vincristine, Etoposide, Cytarabine, Cyclophosphamide, Doxorubicin, Vindesine, Hydrocortisone, Prednisone	PETHEMA Foundation, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea	Mature B-Cell Leukemia Burkitt Type, Burkitt Lymphoma (BL), Unclassifiable Lymphoma Between DCBL and BL	01/24	01/24
PETHEMA LAL-2019, NCT04179929: Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults	Recruiting	N/A	300	Europe	Pediatric-type of chemotherapy, allogeneic HSCT	PETHEMA Foundation	Acute Lymphoblastic Leukemia	11/26	02/27